koto_feja
Corbus Pharma (CRBP) lost ~10% in the premarket on Tuesday after the Norwood, Massachusetts-based biotech announced the latest data from a Phase 1/2 trial for CRB-701 (SYS6002), its lead asset targeting solid tumors.
Citing an April 1, 2026, data cut selected for